Related Experiment Video
Updated: Jan 16, 2026

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
Published on: September 27, 2024
Association of Remnant Cholesterol Inflammation Index with Cardiovascular Risks and All-Cause Mortality in
Qi-Lin Ma1, Lei-Lei Du2, Jia Peng1
1Department of Cardiovascular Medicine, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Insights
The Remnant Cholesterol Inflammation Index (RCII) predicts mortality and cardiovascular disease (CVD) risk in diabetes and prediabetes. This index combines remnant cholesterol and inflammation, aiding early identification of high-risk individuals.
Area of Science:
- Cardiovascular Medicine
- Metabolic Disorders
- Biomarker Discovery
Background:
- Remnant cholesterol (RC) and low-grade inflammation are known cardiovascular disease (CVD) risk factors in diabetes.
- The combined prognostic impact of RC and inflammation in dysglycemia is not well understood.
- This study investigates the Remnant Cholesterol Inflammation Index (RCII) for risk prediction in diabetes/prediabetes.
Purpose of the Study:
- To evaluate the Remnant Cholesterol Inflammation Index (RCII) as a predictor of all-cause mortality and CVD risk.
- To assess the synergistic effect of remnant cholesterol and hsCRP in individuals with diabetes or prediabetes.
- To identify a novel biomarker for early risk stratification in dysglycemic populations.
Main Methods:
- Utilized data from 2206 US adults with diabetes/prediabetes (NHANES 2015-2018).
- Calculated RCII as [RC (mg/dL) × hsCRP (mg/L)]/10.
- Employed Cox and logistic regression for mortality and CVD risk prediction, respectively.
Main Results:
- Higher RCII quartiles showed graded associations with all-cause mortality (HR 2.45 for Q4 vs. Q1).
- Significant dose-dependent relationships were observed for CVD risk and mortality.
- Subgroup analyses indicated consistent mortality associations and sex-specific CVD interactions.
Conclusions:
- The RCII serves as a valuable biomarker for predicting all-cause mortality and CVD risks in individuals with diabetes or prediabetes.
- The index highlights the combined impact of remnant cholesterol and inflammation on adverse outcomes.
- RCII may facilitate early identification of high-risk individuals for targeted interventions.
Backgruound:
Remnant cholesterol (RC) and low-grade inflammation are established contributors to cardiovascular disease (CVD) risks in diabetes. However, their combined prognostic impact remains unclear in dysglycemia. We evaluated the remnant cholesterol inflammation index (RCII), integrating RC and high-sensitivity C-reactive protein (hsCRP), for predicting mortality and CVD risks in diabetes/prediabetes.
Methods:
This study included 2206 United States adults with diabetes/prediabetes from National Health and Nutrition Examination Survey 2015-2018. RCII was calculated as [RC (mg/dL)×hsCRP (mg/L)]/10. All-cause mortality was tracked via National Death Index until 2019; CVD risk was assessed cross-sectionally. Cox proportional hazard regression determined the hazard ratio (HR) and 95% confidence intervals (CIs) of RCII for all-cause mortality. Logistic regression models estimated the odds ratio (OR) and 95% CIs of RCII for CVD risks.
Results:
For CVD risks, Q4 vs. Q1 demonstrated increased odds (OR, 2.32; 95% CI, 1.23 to 4.37), though per-standard deviation (SD) increments were non-significant (OR, 1.15; 95% CI, 0.98 to 1.35; P=0.083). During a median of 38 months follow-up, higher RCII quartiles showed graded associations with all-cause mortality (Q4 vs. Q1: HR, 2.45; 95% CI, 1.08 to 5.58; per 1-SD increase: HR, 1.21; 95% CI, 1.08 to 1.35). Restricted cubic splines confirmed dose-dependent relationships for CVD risks and all-cause mortality (all P=0.005 for overall). Subgroup analyses revealed consistent mortality associations but sex-specific CVD interactions (P=0.047 for interaction).
Conclusion:
Our study found the RCII as a biomarker for predicting all-cause mortality and CVD risks in individuals with prediabetes or diabetes, highlighting the synergistic effects of RC and low-grade inflammation on adverse outcomes in this population and may facilitate early identification of individuals at heightened risk for CVD.
More Related Videos
Related Concept Videos
Coronary Artery Disease I: Introduction
Cholesterol: Significance and Regulation
Considering cholesterol and...
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis III: Management
Inflammation
Atherosclerosis I: Introduction

